NCT02719132View on ClinicalTrials.gov

Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

Dapagliflozin

Dapagliflozin, 10 mg

DRUG

Metformin

Metformin, up to 2500 mg

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY